Evidence map›Paper›PMID 32743535›Full record

ArticleJournal of translational autoimmunity2020

No evidence of autoimmunity to human OX

Krister Melén, Pinja Jalkanen, Jyrki P Kukkonen, Markku Partinen, Hanna Nohynek, Arja Vuorela, Outi Vaarala, Tobias L Freitag, Seppo Meri, Ilkka Julkunen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational autoimmunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. The immunopathogenesis of narcolepsy type 1.Nature reviews. Immunology · 2024
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Krister MelénInstitute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520, Turku, Finland.
Pinja JalkanenInstitute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520, Turku, Finland.
Jyrki P KukkonenDepartment of Physiology and Department of Pharmacology, Institute of Biomedicine, Faculty of Medicine and Biochemistry and Cell Biology, Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Markku PartinenHelsinki Sleep Clinic, Vitalmed Research Centre Helsinki and Medicum, Faculty of Medicine, University of Helsinki, Finland.
Hanna NohynekInfectious Disease Control and Vaccination Unit, Finnish Institute for Health and Welfare, Helsinki, Finland.
Arja VuorelaReseach Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki.
Outi VaaralaReseach Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki.
Tobias L FreitagDepartment of Bacteriology and Immunology and Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Seppo MeriDepartment of Bacteriology and Immunology and Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Ilkka JulkunenInstitute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520, Turku, Finland.
University of Helsinki · FIUniversity of Turku · FIFinnish Institute for Health and Welfare · FITurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Narcolepsy type 1, likely an immune-mediated disease, is characterized by excessive daytime sleepiness and cataplexy. The disease is strongly associated with human leukocyte antigen (HLA) DQB1∗06:02. A significant increase in the incidence of childhood and adolescent narcolepsy was observed after a vaccination campaign with AS03-adjuvanted Pandemrix influenza vaccine in Nordic and several other countries in 2010 and 2011. Previously, it has been suggested that a surface-exposed region of influenza A nucleoprotein, a structural component of the Pandemrix vaccine, shares amino acid residues with the first extracellular domain of the human OX

Indexed as

AutoimmunityInfluenza A virus nucleoproteinNarcolepsyOX1OX2Pandemrix vaccination

Identifiers

PMID32743535
PMCPMC7388359
OpenAlexW3021865330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.